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The highly infectious and deadly pathogen, Francisella tularensis, is classified by the
CDC as a Category A bioterrorism agent. Inhalation of a single bacterium results in an
acute pneumonia with a 30–60% mortality rate without treatment. Due to the prevalence
of antibiotic resistance, there is a strong need for new types of antibacterial drugs.
Resazurin is commonly used to measure bacterial and eukaryotic cell viability through
its reduction to the fluorescent product resorufin. When tested on various bacterial taxa
at the recommended concentration of 44µM, a potent bactericidal effect was observed
against various Francisella and Neisseria species, including the human pathogens type
A F. tularensis (Schu S4) and N. gonorrhoeae. As low as 4.4µM resazurin was sufficient
for a 10-fold reduction in F. tularensis growth. In broth culture, resazurin was reduced to
resorufin by F. tularensis. Resorufin also suppressed the growth of F. tularensis suggesting
that this compound is the biologically active form responsible for decreasing the viability of
F. tularensis LVS bacteria. Replication of F. tularensis in primary human macrophages and
non-phagocytic cells was abolished following treatment with 44µM resazurin indicating
this compound could be an effective therapy for tularemia in vivo.
Keywords: Francisella, resazurin, antibiotic, Neisseria, resorufin, tularemia, antibacterial, macrophages
INTRODUCTION
Francisella tularensis is the causative agent of the zoonotic dis-
ease tularemia (Oyston et al., 2004). This disease is endemic in
North America, Europe, and Asia with outbreaks often associ-
ated with the handling of infected animals or transmission by
arthropod vectors (Sjostedt, 2007; Oyston, 2008). The Centers for
Disease Control and Prevention has categorized F. tularensis as a
Category A bioterrorism agent due to its ease of aerosolization,
low infectious dose, and high mortality rate (McLendon et al.,
2006). Inhalation of fewer than 10 bacteria results in an acute
pneumonia that is lethal in 30–60% of individuals if left untreated
(Dennis et al., 2001; McLendon et al., 2006).
When implemented early in infection, antibiotics are effec-
tive at reducing the case fatality rate for tularemia (Dennis et al.,
2001; Barry et al., 2009). Aminoglycosides are commonly pre-
scribed, specifically streptomycin or gentamicin, although tetra-
cyclines and fluoroquinolones also have antimicrobial activity
against F. tularensis (Nigrovic and Wingerter, 2008; Oyston,
2009). Tetracyclines, however, are associated with high relapse
rates in tularemia patients (Thomas and Schaffner, 2010). Since
this disease is often misdiagnosed due to its generic symptoms,
antibiotic treatment may be delayed resulting in reduced survival
(Barry et al., 2009). There is also a potential for the introduction
of antibiotic-resistant strains (Oyston, 2009). While a tularemia
vaccine is available (live vaccine strain, LVS), it is not currently
licensed for use in the United States (Conlan and Oyston, 2007).
Due to these concerns, there is an increased interest in developing
alternative therapies for tularemia.
Resazurin, the active compound in alamarBlue®, has been used
for decades to measure proliferation and cytotoxicity in prokary-
otic and eukaryotic cells (Page et al., 1993; Ahmed et al., 1994;
O’Brien et al., 2000). In metabolically active cells, this blue, non-
fluorescent dye is reduced to the pink and highly fluorescent com-
pound resorufin allowing for a quantitative measurement of cell
viability (Figure 1) (O’Brien et al., 2000). Upon use of resazurin
to monitor F. tularensis viability in culture at the recommended
concentration of 44µM,we discovered a novel antibacterial activ-
ity for this compound. Resazurin, and its reduced derivative
resorufin, decreased the number of viable F. tularensis bacteria in
broth culture by 100-fold after 1 day of cultivation. Growth of
other bacterial genera was unaffected by this compound with the
exception of Neisseria species, particularly the human pathogen
N. gonorrhoaea. Resazurin also limited replication of F. tularensis
in humanmacrophages and non-phagocytic cells highlighting the
potential use of this compound as a novel antibacterial therapy
in vivo.
MATERIALS AND METHODS
BACTERIAL STRAINS AND GROWTH CONDITIONS
Bacterial strains used in this study are listed in Table 1. Bacteria
grown on solid media were used to inoculate chocolate II agar
plates or TSBc [trypticase soy broth (BD Biosciences) containing
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FIGURE 1 | The reduction of resazurin to resorufin.
Table 1 | Bacterial strains used in this study.
Bacterial strain Source
Francisella tularensis subsp. holarctica
live vaccine strain
Karen Elkins
F. tularensis subsp. tularensis Schu S4
(NR-643)
NIH BEI Resources Repositorya
F. novicida U112 Karen Elkins
F. philomiragia (ATCC 25018) ATCC
Neisseria gonorrhoeae (ATCC 9793) ATCC
N. polysaccharea (ATCC 43768) ATCC
N. sicca (ATCC 9913) ATCC
Acinetobacter baumannii (ATCC 19606) ATCC
Pseudomonas aeruginosa 1244 Peter Castric
Escherichia coli WLU-MCCb
Salmonella typhimurium WLU-MCCb
Staphylococcus aureus WLU-MCCb
Listeria monocytogenes EGD Douglas Drevets
Klebsiella pneumoniae WLU-MCCb
Streptococcus pneumoniae, clinical
isolate
Robert Shanks
aNational Institutes of Health Biodefense and Emerging Infections (NIH BEI)
Research Resources Repository, National Institute of Allergy and Infectious
Diseases.
bWLU-MCC = West Liberty University Microbiology Culture Collection, bacterial
species routinely verified by standard metabolic and physiological tests.
0.1% L-cysteine hydrochloride monohydrate (Fisher)] supple-
mented with or without various concentrations of resazurin
sodium salt (Acros Organics, dissolved in water) or resorufin
(Tokyo Chemical Industries, dissolved in dimethyl sulfoxide).
Chocolate II agar plates were incubated at 37◦C with 5% CO2
(Francisella species, Neisseria species, and Listeria monocytogenes)
or without CO2 (all other bacteria) for 1–3 days while broth cul-
tures were incubated at 37◦C with shaking. All work with Schu
S4 was conducted under BSL-3 conditions at the University of
Pittsburgh with approval from the CDC Select Agent Program.
REDUCTION OF RESAZURIN TO RESORUFIN BY F. tularensis
F. tularensis was cultured in TSBc supplemented with 44µM
resazurin at 37◦C with shaking for 24 h. At select timepoints,
a Spectronic 200 Spectrophotometer was used to measure the
absorbance at 600 nm and 570 nm to detect the presence of
resazurin and resorufin, respectively. The ratio of these two
optical densities was used to evaluate reduction of resazurin to
resorufin over time.
GROWTH OF F. tularensis IN HUMANMACROPHAGES AND HEK293
CELLS
Human monocytes purified from buffy coats from blood dona-
tions (New York Blood Center, Long Island City, NY and the
Central Blood Bank, Pittsburgh, PA) were differentiated into
macrophages as described previously (Carlson et al., 2007, 2009;
Horzempa et al., 2008a,b, 2010; Robinson and Nau, 2008;
Robinson et al., 2010, 2012; Russo et al., 2011; Schmitt et al.,
2012). Macrophages were then washed and resuspended in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 1% human serum AB (Gemini Bio-Products), 25mM
HEPES (Cellgro), and 1% glutamine dipeptide (Fisher Scientific).
HEK293 cells (ATCC CRL-1573), a non-phagocytic kidney
epithelial cell line (Tachado et al., 2007), were cultured in DMEM
supplemented with 10% fetal bovine serum (Gibco), 25mM
HEPES, and 1% glutamine dipeptide with 100U/ml penicillin-
streptomycin (Cellgro). HEK293 cells were passaged at least once
without antibiotics prior to use. To assess intracellular growth,
gentamicin protection assays were performed (Small et al., 1987).
Macrophages and HEK293 cells were seeded in Primaria 96-
well culture dishes (BD Biosciences) at a density of 5 × 104
cells/well. F. tularensis bacteria recovered from broth cultures
described above were adjusted to an OD600 of 0.3 (approxi-
mately 1.5 × 109 CFU/ml) and diluted to achieve a multiplicity
of infection (MOI) of 500. The actual MOI was measured by plat-
ing serial dilutions of the inoculum on chocolate II agar plates.
Cells were incubated with this MOI for 2 h yielding an infec-
tion rate of >80% (Carlson et al., 2007; Horzempa et al., 2008a)
either in the absence or presence of 44µM resazurin. After this
time period, cells were incubated with gentamicin (100µg/ml)
for 30min to kill extracellular bacteria and then washed twice
with warm Hanks balanced salt solution (Cellgro). Fresh cul-
ture media with or without resazurin (44µM) was then added
and cells were incubated for another 22 h at 37◦C with 5% CO2.
At the indicated timepoints, cells were lysed with 0.02% sodium
dodecyl sulfate and viable CFU were measured as described
below.
ENUMERATION OF BACTERIA
At the indicated timepoints, a portion of the F. tularensis broth
cultures or human cell lysates were serially diluted and plated onto
chocolate II agar plates. Plates were incubated at 37◦C at 5% CO2
for 2–3 days and individual colonies were enumerated. The limit
of detection was 100CFU per ml for broth culture or per 5 × 104
cells for intracellular growth assays.
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ANALYTICAL METHODS
Statistically significant differences in bacterial number were deter-
mined by a Student’s t-test or ANOVA followed by a Dunnett’s
or Bonferroni post-hoc test (GraphPad Prism 5). The chemcial
structures of resazurin, resorufin, and acridine were drawn using
ChemDraw Pro 13.0 for comparative analysis.
RESULTS
RESAZURIN SELECTIVELY INHIBITS GROWTH OF FRANCISELLA AND
NEISSERIA SPECIES
Resazurin has been used previously as an indicator of cell growth
for various bacterial species (Mendoza-Aguilar et al., 2012; Bassett
et al., 2013; Bauer et al., 2013; Lall et al., 2013). We were inter-
ested in using this compound to monitor viability of F. tularensis
in broth culture over time. Unexpectedly, no viable bacteria were
detected 24 h post-inoculation following inclusion of resazurin
in TSBc cultures of F. tularensis LVS at the concentration rec-
ommended by the manufacturer (44µM) (data not shown).
This concentration of resazurin had no effect on the growth of
E. coli or P. aeruginosa cultivated in the same medium (data not
shown). The antimicrobial activity of resazurin on F. tularen-
sis LVS was not specific to TSBc as these bacteria were also
unable to grow on chocolate II agar plates containing this com-
pound (Table 2) as well as a chemically defined medium (data
not shown). Lowering the resazurin concentration to as little as
4.4µM still resulted in a 10-fold reduction in viable F. tularen-
sis LVS compared to growth medium alone (Figure 2). These
data suggest that resazurin exhibits bactericidal activity against F.
tularensis.
To determine whether the antibacterial effect of resazurin was
specific to this organism, an assortment of bacteria from diverse
taxa were plated on chocolate II agar plates supplemented with
Table 2 | Resazurin inhibits the growth of Francisella and Neisseria
species on chocolate II agar.
Resazurin Concentration
Bacterial strain 0µM 44µM
Francisella tularensis Schu S4 + −
F. tularensis LVS + −
F. novicida + +
F. philomiragia + +
Neisseria gonorrhoeae + −
N. polysaccharea + −
N. sicca + −
Acinetobacter baumannii + +
Pseudomonas aeruginosa 1244 + +
Escherichia coli + +
Salmonella typhimurium + +
Staphylococcus aureus + +
Listeria monocytogenes + +
Klebsiella pneumoniae + +
Streptococcus pneumoniae + +
+, robust growth.
−, no growth.
resazurin. All bacterial species tested were able to grow in the pres-
ence of 44µM resazurin except F. tularensis and Neisseria species
(Table 2). These data suggest that resazurin is an antimicrobial
compound with specificity for F. tularensis and Neisseria species
bacteria.
REDUCTION OF RESAZURIN TO RESORUFIN DOES NOT ALTER ITS
ANTIBACTERIAL ACTIVITY
As previously mentioned, viable cells are capable of converting
resazurin to resorufin. To determine whether this reduction was
occurring in F. tularensis LVS cultures, the ratio of resorufin
to resazurin was measured over time using the optical densi-
ties at 570 nm (resorufin) and 600 nm (resazurin). The ratio of
resorufin to resazurin increased 3-fold within 2 h of inocula-
tion with F. tularensis LVS, reaching a maximum ratio of 5 four
hours post-inoculation which was maintained for the remainder
of the 24 h period (Figure 3A). This suggested F. tularensis LVS
was reducing resazurin to resorufin. Therefore, we determined if
resorufin also exhibited antibacterial activity against F. tularensis.
Following 24 h of culture in the presence of resorufin, the number
of F. tularensis LVS bacteria was significantly reduced compared
to growth medium supplemented with vehicle alone (Figure 3B).
A similar decrease in bacterial number was observed follow-
ing incubation of F. tularensis LVS with resazurin (Figure 3B).
These data suggest resorufin is also bactericidal against F. tularen-
sis. To evaluate whether resazurin must first be converted to
resorufin to exhibit antibacterial activity, we measured viable
F. tularensis LVS bacteria over time grown in the presence of
resazurin and resorufin. In cultures treated with resazurin, reduc-
tion of this compound to resorufin was observed as early as
FIGURE 2 | Resazurin has an antimicrobial effect on F. tularensis LVS.
Bacteria were cultivated in tryptic soy broth supplemented with 0.1%
cysteine HCl (TSBc) in the presence or absence of resazurin at the
designated concentrations for 24 h. Cultures were then diluted and plated
to determine the number of viable F. tularensis LVS bacteria 24 h post
inoculation. Data shown are mean ± s.e.m. from three individual
experiments. The limit of detection was 100CFU per ml. Statistically
significant differences in growth post-inoculation were determined by
One-Way ANOVA followed by Dunnett’s post-hoc test (∗∗∗p < 0.001
compared to 0µM resazurin).
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FIGURE 3 | F. tularensis LVS reduces resazurin to resorufin which also
inhibits bacterial growth. F. tularensis LVS bacteria were cultivated in TSBc
that was treated with resazurin, resorufin, or the solvent vehicle (DMSO). (A)
Conversion of resazurin (absorbance at 600 nm) to resorufin (absorbance at
570 nm) in F. tularensis LVS cultures over 24 h. (B,C) F. tularensis LVS cultures
were diluted and plated to determine the number of viable bacteria at 24 h (B) or
the indicated timepoints (C). Data shown are mean ± s.e.m. from three
individual experiments. The limit of detection was 100CFU per ml. Statistically
significant differences in growth post-inoculation were determined by (B)
One-Way ANOVA followed by Dunnett’s post-hoc test (∗∗p < 0.01 compared to
TSBc) or (C) Two-Way ANOVA followed by Bonferroni comparison of means
(p < 0.05 for Control vs. Resazurin and Control vs. Resorufin for 12–24 h).
2 h post-inoculation (Figure 3A). However, a decline in viable
bacteria occurred 8 h post-inoculation, reaching statistical sig-
nificance by 12 h (Figure 3C). Moreover, a similar decrease in
bacterial viability was observed in cultures initially treated with
resorufin (Figure 3C). No significant differences in viable bac-
teria were observed between F. tularensis cultures treated with
either resazurin or resorufin at any of the time points (Figure 3C).
Because resazurin and resorufin both exhibit a similar antimicro-
bial effect on F. tularensis, this suggests that the redox reaction
itself is not responsible for the observed bactericidal activity.
However, the data indicating that resazurin is rapidly converted
to resorufin, while the drop in viability occurs most drastically
after 8 h, may suggest that resorufin is the biologically active
form responsible for decreasing the viability of F. tularensis LVS
bacteria.
RESAZURIN LIMITS INTRACELLULAR REPLICATION OF F. tularensis IN
PHAGOCYTIC AND NON-PHAGOCYTIC CELLS
In an infected host, F. tularensis resides and replicates inside
macrophages (Elkins et al., 2007). Therefore, resazurin must
be able to limit intracellular growth of this bacterium in these
cells in order to be an effective therapeutic. To test this, pri-
mary human macrophages were infected with F. tularensis LVS,
and viable intracellular bacteria were quantified using a gentam-
icin protection assay as described previously (Horzempa et al.,
2008a, 2010). Cells were treated with 44µM resazurin during
the entire assay (+Rz), beginning 2 h post-infection (+2 h Rz),
or left untreated. Both resazurin treatments resulted in a sig-
nificant decrease in viable F. tularensis LVS bacteria over 22 h
(Figure 4A). Visible observation of the macrophages 24 h post-
infection indicated resazurin was reduced to resorufin, although
this phenomenon was not quantified (data not shown). This
suggested that the macrophages were still viable, and that the
combination of resazurin and F. tularensis LVS did not culminate
in undesirable toxicity. F. tularensis is also capable of infecting and
replicating in non-phagocytic cells like epithelial cells and hep-
atocytes which is sufficient for pathogenesis (Horzempa et al.,
2010). We next determined whether resazurin was also capable
FIGURE 4 | Resazurin exhibits antimicrobial activity on intracellular
F. tularensis LVS. Primary human macrophages (A) or HEK293 (B) cells
were infected with F. tularensis LVS bacteria using a gentamicin protection
assay. Cells were treated with 44µM resazurin during the entire assay (+
Rz), at 2 h post-infection (+ 2h Rz), or were untreated. Data shown are
mean ± s.e.m. and representative of three independent experiments. The
limit of detection was 100 CFU. Statistically significant differences in
growth at 24 h post-infection were determined by Two-Way ANOVA with
Dunnett’s post-hoc test (∗∗∗p < 0.001).
of inhibiting growth of F. tularensis LVS in non-phagocytic cells.
To test this, a human kidney epithelial cell line HEK293 was
used as a model for non-phagocytic cells. Similar to the results
obtained with macrophages, treatment with resazurin signifi-
cantly reduced the number of viable F. tularensis LVS bacteria in
HEK293 cells 22 h post-infection (Figure 4B). In an additional
experiment, no viable F. tularensis LVS bacteria were detected
fromHEK293 cells at 72 h post infection following treatment with
44µM resazurin (data not shown). Based on these data, resazurin
exhibits antimicrobial activity against intracellular F. tularensis
bacteria.
DISCUSSION
The prevalence of antibiotic resistance in today’s society high-
lights the need for new classes of antibiotics (Bassetti et al.,
2013). Here, we identified an unanticipated bactericidal activity
for a compound commonly used to measure cellular viability.
Resazurin inhibited growth of only F. tularensis and Neisseria
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FIGURE 5 | Chemical structures of resazurin and acridine.
species in vitro, notably the human pathogens, type A F. tularensis
(Schu S4) andN. gonorrhoeae. The fact that resazurin targets such
a limited array of pathogenic organisms is extremely desirable
from the standpoint of limiting the potential of drug resistance
in the future.
Most antibiotics target pathways that are conserved by numer-
ous bacterial species like cell wall or protein synthesis (Lewis,
2013). Resazurin is unique in that it only exhibits antimicro-
bial activity against two types of bacteria tested in this work,
F. tularensis and Neisseria (Table 2). Aside from their fastidi-
ous nature, there are no apparent similarities between these two
groups of bacteria that distinguish them from the other bacte-
rial genera tested to suggest a mechanism of action. In culture,
resazurin is reduced to resorufin by F. tularensis LVS, however,
this chemical reaction is not responsible for the decline in viabil-
ity since both compounds are equivalently bactericidal (Figure 3).
Examination of the chemical structure of resazurin elucidated
similarities to acridine (Figure 5). Many acridine derivatives were
used as antibacterial agents during World War II (Wainwright,
2001). The planar area of the tricyclic acridine nucleus allows
for intercalation of DNA resulting in its bactericidal activity
(Wainwright, 2001). The possibility that resazurin functions in
a similar fashion is currently being investigated.
In the human host, F. tularensis and N. gonorrhoeae reside
inside host cells (Post et al., 2002; Oyston, 2008; Horzempa et al.,
2011). Therefore, resazurin must be able to penetrate infected
host cells to maintain its antibacterial activity in vivo. During
the in vitro infection assays, resazurin was capable of limiting
intracellular replication of F. tularensis in both phagocytic and
non-phagocytic cells (Figure 4). While resazurin was converted
to resorufin in these assays, the reduction of this compound by
the host cells did not decrease the potency of the drug, which
is consistent with the data indicating that both derivatives are
bactericidal (Figures 3, 4). Resazurin has been tested for toxic-
ity in mice at a dose 100-fold higher than that used in this study
and shown to be relatively well-tolerated (Lutty, 1978). Another
recently developed antibacterial compound, fosmidomycin that
was effective at killing intracellular Francisella bacteria in vitro,
also prolonged survival following a lethal challenge in an animal
model (McKenney et al., 2012). The data presented here strongly
suggest that resazurin will be an effective therapeutic for use
during an in vivo F. tularensis or Neisseria infection, and substan-
tiate the need for pre-clinical animal trials using mouse models of
infection.
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